CUMBERLAND PHARMACEUTICALS, INC.

Basic Information

2525 WEST END AVE, STE 950
NASHVILLE, TN, 37203-1608

http://www.cumberlandpharma.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 069532880
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 35


  1. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    Amount: $224,910.00

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this dise ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation

    Amount: $246,084.00

    DESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation ...

    STTR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government